Triple-Drug cocktail takes aim at rare, aggressive cancers
NCT ID NCT07510594
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study aims to see how many patients' tumors shrink significantly. It will enroll 48 adults who have not had prior treatment for advanced disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy), and chemotherapy (carboplatin or cisplatin plus etoposide)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for patients with these rare and aggressive cancers, potentially improving tumor shrinkage rates.
- What could go wrong
- This is a small, early-phase (Phase 2) single-center study with only 48 participants. The combination may cause significant side effects, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo targets rare, aggressive lung cancer
- New drug cocktail aims to tame rare lung cancer
- Engineered immune cells take aim at deadly lung cancer
- Engineered immune cells take aim at tough lung cancer
- Radioactive drug targets tough lung cancers in early trial
- New drug combo aimed at tough cancers pulled before starting